Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,529.50
Bid: 1,531.50
Ask: 1,532.00
Change: 3.50 (0.23%)
Spread: 0.50 (0.033%)
Open: 1,537.00
High: 1,541.50
Low: 1,523.00
Prev. Close: 1,526.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-European stocks: Unloved for the past two decades, what about the next?

Wed, 13th Jan 2021 15:45

* Major U.S. stock indexes churn near flat line, Nasdaq up
front

* Utilities leads gainers among S&P sectors; materials lag

* Euro STOXX 600 edges higher

* Dollar, gold, crude advance

* US 10-Year Treasury yield ~1.10%

Jan 13 - Welcome to the home for real-time coverage of
markets brought to you by Reuters reporters. You can share your
thoughts with us at markets.research@thomsonreuters.com

EUROPEAN STOCKS: UNLOVED FOR THE PAST TWO DECADES, WHAT
ABOUT THE NEXT? (1045 EST/1545 GMT)

While Wall Street and Asian stocks are at all-time highs,
Europe is clearly lagging and has been for the past 20 years.

The old continent's share in the value of global equities
has almost halved over the past two decades, to 17% from over
30%, as per BofA Global Research.

The U.S. bank blames it on the absence of FAANGs, bigger
exposure to cheap sectors like banks and energy, aging
population, pressures from de-globalisation and climate change,
slower GDP growth versus rest of the developed world.

Apparently, Apple sells more watches than the
entire Swiss watch industry, and Cisco's market cap is
more than that of leading telecom service providers in UK,
France, Spain, Italy and Switzerland, combined, according to the
note.

What does the future look like for European investors? BofA
lists a handful of sectors that could shape the markets in the
next decade.

FANGMAN to GRANS: While U.S. remains a FANGMAN
market(Facebook, Amazon, Alphabet,
Microsoft, Apple, Netflix), Europe is
dominated by GRANS (GlaxoSmithKline, Roche,
AstraZeneca, Novartis, Sanofi).
Healthcare has been among the sectors whose markets weightings
have grown in the wake of the pandemic.

CLIMATE ACTION: Eight of the top 10 clean energy companies
by market cap are in Europe, which is also the undisputed leader
of ESG markets.

LUXURY: Luxury companies in Europe are worth more than its
autos sector, while in 2009 they were worth less than one-third;
LVMH is valued more than 4x Daimler, the largest
European carmaker.

GOLDEN AGE FOR EU CLEANTECH: 85% of Europe's electricity is
expected to be from zero-carbon sources by 2030 vs. 57% in 2020;
BofA sees tailwind from economics, policy, funding, tech
innovation and consumer adoption.

Even so, BofA says Europe's pro-cyclical nature and a weak
domestic growth means that European EPS only outperforms during
periods of strong global growth, and it's lack of exposure to
high-growth sectors like technology will drive its structural
underperformance in future.

(Sruthi Shankar)

*****

U.S. STOCKS WAFFLE, THEN HEAD SOUTH (1008 EST/1508 GMT)

Wall Street waffled on Wednesday after the opening bell,
strobing between green then red - but seemed to decide, a
half-hour into the session, to settle in negative territory.

There was little in the way of a catalyst to turn investor
moods sour or sweet. The ongoing vaccine rollout and
expectations for more generous fiscal stimulus from the incoming
Biden administration was again offset by the resurgent pandemic
and the unfolding drama in Washington.

The U.S. House of Representatives is expected to vote for
the second time within 12 months to impeach President Donald
Trump, this time for inciting an insurrection.

That insurrection caught the attention of U.S. Federal
Reserve officials, who said on Tuesday that while concerns about
continued violence pose a risk, but the transition to a new
administration on Jan. 20, and a likely accelerating vaccine
rollout have left them optimistic.

On the economic front, CPI data appeared to confirm tepid
inflation that can keep the Fed's monetary policy accommodative
for the foreseeable future.

In a reversal from Tuesday, economically sensitive small
caps and transports are underperforming the
broader market.

Here's your opening snapshot:
(Stephen Culp)

*****

TECH VS FINANCIALS: COMING BACK TO EARTH (0900 EST/1400 GMT)

After an unprecedented streak of consecutive higher monthly
closes that ended in August of last year, the S&P 500 tech
sector / S&P 500 financial sector ratio has
been coming back to earth.

This, as value took the reins from growth.

Indeed, the tech / financials ratio ended at 5.23 in August,
after having logged 11-straight higher monthly closes. (Click on
chart below)

That's one more month than the 10-month win streak the ratio
recorded into the Nasdaq/tech sector October 2007 top.
It was also this ratio's longest streak of higher monthly closes
using Refinitiv data back to 1989.

Additionally, through August, the ratio ended above its
upper monthly Bollinger Band (BB) for eight straight months
(more than two standard deviations above its 20-month moving
average). That was also its longest such streak going back to
1989. Thus, the ratio appeared especially high on a relative
basis.

With September's downtick, the ratio came back inside the
upper monthly BB, suggesting potential for a more significant
reversal.

Now, at 4.36, the ratio is on track to fall for a 5th
straight month. A continued decline to even just meet the rising
20-month moving average, now around 3.99, would suggest
additional tech underperformance relative to financials, and
with this, likely further growth underperformance vs value.

(Terence Gabriel)

*****

FOR WEDNESDAY'S LIVE MARKETS' POSTS PRIOR TO 0900 EST/1400
GMT - CLICK HERE:

(Terence Gabriel is a Reuters market analyst. The views
expressed are his own)

More News
16 Feb 2023 23:17

Judge weighs key evidence ahead of first Zantac cancer trial

Feb 16 (Reuters) - Lawyers for a man who alleges he developed bladder cancer after taking GSK Plc's heartburn drug Zantac urged a California judge on Thursday to allow expert testimony linking the drug to the illness at an upcoming trial.

Read more
16 Feb 2023 19:38

Judge to weigh key evidence ahead of first Zantac cancer trial

Feb 16 (Reuters) - GSK Plc is expected to urge a California judge on Thursday to limit what expert testimony jurors can hear in the first trial over claims that the company's heartburn drug Zantac caused cancer.

Read more
16 Feb 2023 16:05

Pfizer/BioNTech, Moderna gear up for 2024 London trial over COVID vaccine patents

LONDON, Feb 16 (Reuters) - Pfizer Inc and its German partner BioNTech SE are gearing up for a 2024 trial with Moderna Inc at London's High Court in competing patent lawsuits over their rival COVID-19 vaccines.

Read more
16 Feb 2023 15:47

UK dividends calendar - next 7 days

Friday 17 February 
abrdn Asian Income Fund Ltddividend payment date
Focusrite PLCdividend payment date
JPMorgan Asia Growth & Income PLCdividend payment date
JPMorgan Japan Small Cap Growth & Income PLCdividend payment date
Murray International Trust PLCdividend payment date
Victrex PLCdividend payment date
Monday 20 February 
AEW UK REIT PLCdividend payment date
Invesco Bond Income Plus Ltddividend payment date
Tuesday 21 February 
no events scheduled 
Wednesday 22 February 
no events scheduled 
Thursday 23 February 
abrdn Asia Focus PLCex-dividend payment date
abrdn Equity Income Trust PLCex-dividend payment date
Alumasc Group PLCex-dividend payment date
AstraZeneca PLCex-dividend payment date
Barclays PLCex-dividend payment date
BlackRock Throgmorton Trust PLCex-dividend payment date
Brunner Investment Trust PLCex-dividend payment date
FRP Advisory Group PLCex-dividend payment date
Gateley Holding PLCex-dividend payment date
GSK PLCex-dividend payment date
JPMorgan European Growth & Income PLCex-dividend payment date
Land Securities Group PLCex-dividend payment date
Momentum Multi-Asset Value Trust PLCex-dividend payment date
Primary Health Properties PLCdividend payment date
Redrow PLCex-dividend payment date
Standard Chartered PLCex-dividend payment date
Supermarket Income REIT PLCdividend payment date
Unilever PLCex-dividend payment date
Witan Investment Trust PLCex-dividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
16 Feb 2023 09:04

GSK hails positive phase III trial results for RSV vaccine candidate

(Alliance News) - GSK PLC on Thursday said a New England Journal of Medicine publication announced positive phase III trial results for its respiratory syncytial virus vaccine candidate for older adults.

Read more
16 Feb 2023 00:01

embargoed-Britain's NICE to speed up reviews of COVID-19 treatments

LONDON, Feb 16 (Reuters) - Britain's agency that determines if medicines should be used in the National Health Service (NHS) said on Thursday it is speeding up how it decides if COVID-19 therapies are still effective against circulating variants.

Read more
10 Feb 2023 15:09

Unilever says prices hikes will continue into this year, easing in H2

Unilever sees higher prices in 2023, moderating in second half

*

Read more
10 Feb 2023 09:52

LONDON BROKER RATINGS: Shell, Glencore, Smurfit and abrdn ratings cut

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
10 Feb 2023 08:29

Berenberg raises target price on GSK

(Sharecast News) - Analysts at Berenberg raised their target price on drugmaker GSK from £15.80 each to £17.30 on Friday, citing "steady progress".

Read more
10 Feb 2023 08:04

TOP NEWS: GSK's Jemperli wins approval and trial evaluation in US

(Alliance News) - GSK PLC on Friday said its drug Jemperli won a regular approval for a form of endometrial cancer and is set to be evaluated for a form of advanced rectal cancer in the US.

Read more
10 Feb 2023 07:07

GSK's endometrial cancer treatment receives full FDA approval

(Sharecast News) - Drugmaker GSK's mismatch repair-deficient recurrent or advanced endometrial cancer treatment has been granted full approval by the Food and Drug Administration.

Read more
8 Feb 2023 06:00

Why Europe's drug shortages may get worse

Most European countries reporting shortages of antibiotics

*

Read more
2 Feb 2023 09:44

Roche warns 2023 profits will fall on $5 bln COVID sales hit

2023 outlook weaker than expected - analysts

*

Read more
2 Feb 2023 09:26

GSK gets FDA approval for drug to treat anaemia in adults on dialysis

(Alliance News) - GSK PLC on Thursday said its Jesduvroq drug has been approved by the US Food & Drug Administration for anaemia of chronic kidney disease in adults on dialysis.

Read more
2 Feb 2023 09:19

LONDON BROKER RATINGS: Goldman Sachs cuts Standard Chartered

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.